title: Novartis Reply to the ATMOSPHERE Data Monitoring Committee.
authors.affiliation: Novartis Pharma, Basel, Switzerland paul.aftring@novartis.com.
authors.forename: Gervais
authors.initials: G
authors.lastname: Tougas
authors.affiliation: Novartis Pharma, Basel, Switzerland paul.aftring@novartis.com.
authors.forename: R Paul
authors.initials: RP
authors.lastname: Aftring
mesh_terms: D000577:Amides / Q000009:adverse effects*; D026661:Clinical Trials Data Monitoring Committees; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D005650:Fumarates / Q000009:adverse effects*; D006801:Humans; D016032:Randomized Controlled Trials as Topic
chemical_list: D000577:Amides; D005650:Fumarates